NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis $51.56 +3.31 (+6.85%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Spruce Biosciences Stock (NASDAQ:SPRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spruce Biosciences alerts:Sign Up Key Stats Today's Range$49.00▼$52.7150-Day Range$48.25▼$70.5052-Week Range$4.35▼$240.00Volume45,079 shsAverage Volume53,330 shsMarket Capitalization$70.73 millionP/E RatioN/ADividend YieldN/APrice Target$186.60Consensus RatingModerate Buy Company Overview Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials. The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels. In parallel, Spruce is developing nevanimibe, an adrenocortical hormone synthesis inhibitor, to further address the hormonal imbalances associated with CAH. Both candidates have demonstrated promising safety and efficacy profiles in early-phase studies. Since its founding in 2017, Spruce Biosciences has established a global clinical infrastructure with trial sites across North America and Europe, enabling the company to enroll patients in its pivotal studies efficiently. The company collaborates with academic centers and patient advocacy groups to support trial design and patient recruitment, underscoring its commitment to advancing care for individuals living with rare endocrine disorders. Under the leadership of President and Chief Executive Officer Jonathan Porges, Spruce combines experienced management with a scientific advisory board comprised of experts in endocrinology and drug development. The company’s deliberate strategy of targeting well-defined patient populations aims to streamline regulatory pathways and bring transformative therapies to market for communities with few existing treatment options.AI Generated. May Contain Errors. Read More Spruce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreSPRB MarketRank™: Spruce Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 608th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingSpruce Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialSpruce Biosciences has a consensus price target of $186.60, representing about 261.6% upside from its current price of $51.61.Amount of Analyst CoverageSpruce Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Spruce Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($31.02) to ($14.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.70% of the float of Spruce Biosciences has been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 1.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently increased by 14.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-1.16 News SentimentSpruce Biosciences has a news sentiment score of -1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Spruce Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spruce Biosciences' insider trading history. Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRB Stock News HeadlinesSpruce Biosciences (NASDAQ:SPRB) Price Target Cut to $150.00 by Analysts at Citizens JmpMay 15, 2026 | americanbankingnews.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSaudi Arabia just broke its 50-year dollar arrangementSaudi Arabia has quietly walked away from its 1974 petrodollar agreement with the U.S. - the pact that required every nation to stockpile dollars just to buy oil. The Saudis have since inked a $7 billion currency swap with Beijing, begun clearing oil in digital yuan, and joined China's mBridge settlement network. As dollar demand softens, Treasury yields are already creeping toward 4.4% - and gold has historically been the clearest beneficiary. But the smartest way to position isn't bullion. There's a discounted vehicle offering gold exposure at a fraction of the cost.May 20 at 1:00 AM | Golden Portfolio (Ad)Craig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comSee More Headlines SPRB Stock Analysis - Frequently Asked Questions How have SPRB shares performed this year? Spruce Biosciences' stock was trading at $87.11 at the beginning of 2026. Since then, SPRB shares have decreased by 40.8% and is now trading at $51.6050. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its quarterly earnings results on Wednesday, May, 13th. The company reported ($8.94) EPS for the quarter, missing analysts' consensus estimates of ($7.93) by $1.01. When did Spruce Biosciences' stock split? Shares of Spruce Biosciences reverse split before market open on Monday, August 4th 2025.The 1-75 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $90 million in an initial public offering on Friday, October 9th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO. Who are Spruce Biosciences' major shareholders? Top institutional shareholders of Spruce Biosciences include ADAR1 Capital Management LLC (4.28%) and Stempoint Capital LP (0.46%). Insiders that own company stock include Holdings A/S Novo and Parkman Healthcare Partners Ll. View institutional ownership trends. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spruce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON). Company Calendar Last Earnings5/13/2026Today5/20/2026AGM 20265/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRB CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees20Year Founded2016Price Target and Rating Average Price Target for Spruce Biosciences$186.60 High Price Target$283.00 Low Price Target$140.00 Potential Upside/Downside+262.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($36.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.97 million Net MarginsN/A Pretax Margin-6,869.30% Return on Equity-155.40% Return on Assets-101.67% Debt Debt-to-Equity Ratio0.16 Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.25 per share Price / Book2.04Miscellaneous Outstanding Shares1,372,000Free Float1,313,000Market Cap$70.69 million OptionableOptionable Beta3.26 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SPRB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredSaudi Arabia just broke its 50-year dollar arrangementSaudi Arabia has quietly walked away from its 1974 petrodollar agreement with the U.S. - the pact that require...Golden Portfolio | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
